Citations

Clear

3030 citation(s) found for "Susan, M".

TAMI-28. DIFFERENTIAL MIGRATION MECHANICS AND IMMUNE RESPONSES OF GLIOMA SUBTYPES
Liu, Chao , Braman, Brooke C , Rathe, Susan K. , Sarver, Aaron L. , Ghaderi, Nima, McMahon, Mariah, Klank, Rebecca, McFarren, Joey, Clark, H. Brent , Rosenfeld, Steven S. , Largaespada, David A. , Shamsan, Ghaidan A , Rathe, Susan K. , McMahon, Mariah , Klank, Rebecca L. , Tschida, Barbara R , Sarkaria, Jann N. , Clark, H Brent , Largaespada, David A. , Odde, David J

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii219-ii219

10.1093/neuonc/noaa215.916 Get It

Abstract In Glioblastoma (GBM), tumor spreading is driven by tumor cells’ ability to infiltrate healthy brain parenchyma, which prevents complete surgical resection and contributes to tumor recurrence. GBM molecular subtypes, classical, proneural and mesenchymal, were shown to strongly correlate with specific genetic alterations (Mesenchymal: NF1; Classical: EGFRVIII; Proneural: PDGFRA). Here we tested the hypothesis that a key mechanistic difference between GBM molecular subtypes is that proneural cells are slow migrating and mesenchymal cells are fast migrating. Using Sleeping Beauty transposon system, immune-competent murine brain tumors were induced by SV40-LgT antigen in combination with either NRASG12V (NRAS) or PDGFB (PDGF) overexpression. Cross-species transcriptomic analysis revealed NRAS and PDGF-driven tumors correlate with human mesenchymal and proneural GBM, respectively. Similar to human GBM, CD44 expression was higher in NRAS tumors and, consistent with migration simulations of varying CD44 levels, ex vivo brain slice live imaging showed NRAS tumors cells migrate faster than PDGF tumors cells (random motility coefficient = 30µm2/hr vs. 2.5µm2/hr, p < 0.001). Consistent with CD44 function as an adhesion molecule, migration phenotype was independent of the tumor microenvironment. NRAS and human PDX/MES tumor cells were found to migrate faster and have larger cell spread area than PDGF and human PDX/PN tumors cells, respectively, in healthy mouse brain slices. Furthermore, traction force microscopy revealed NRAS tumor cells generate larger traction forces than PDGF tumors cells which further supports our theoretical mechanism driving glioma migration. Despite increased migration, NRAS cohort had better survival than PDGF which was attributed to enhanced antitumoral immune response in NRAS tumors, consistent with increased immune cell infiltration found in human mesenchymal GBM. Overall our work identified a potentially actionable difference in migration mechanics between GBM subtypes and establishes an integrated biophysical modeling and experimental approach to mechanically parameterize and simulate distinct molecular subtypes in preclinical models of cancer.
SURG-18. THE IMPACT OF NEUROLOGIC IMPAIRMENTS ON THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION IN NEWLY DIAGNOSED IDH-WILD TYPE GLIOBLASTOMA
Hervey‐Jumper, Shawn L. , Molinaro, Annette M. , Ore, Cecilia Dalle, Brown, Desmond, Zhang, Yalan, Lafontaine, Marisa , Ammanuel, Simon G. , Shai, Anny , Warrier, Gayathri , Rice, Terri, Lin, Yi , Phillips, Joanna, Wrensch, Margaret , Wiencke, John, Bush, Nancy Ann Oberheim , Taylor, Jennie , Butowski, Nicholas , Clarke, Jennifer , Chang, Susan M. , Theodosopoulos, Philip V. , Molinaro, Annette M. , Ore, Cecilia L. Dalle, Morshed, Ramin A. , Warrier, Gayathri , Crane, Jason C. , Wiencke, John K. , Aghi, Manish Kumar , Berger, Mitchel S.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii207-ii207

10.1093/neuonc/noaa215.865 Get It

Abstract BACKGROUND The prognostic importance of maximal resection of contrast enhancing and non-contrast enhancing disease has been established. Nonetheless, glioblastomas exist within the framework of complex neural circuitry serving cognition, movement, and behavior consequential leading to neurological impairments. The prognostic importance of neurological impairments on survival remains poorly understood. METHODS This is a retrospective, single cohort study from UCSF including 316 eligible patients diagnosed over 20 years with 9.6 years of follow-up. All patients underwent surgical resection for newly diagnosed glioblastoma for whom survival, molecular, preoperative and postoperative MRI images, and clinical data were available. All patients had chemoradiation treated IDH-wild-type glioblastoma with available preoperative and 1-month post-surgical resection neurological outcomes. We employed survival models and recursive partitioning (RPA) to investigate multivariate relationships of overall survival (OS). RESULTS Preoperative neurological impairments were present in 75.6% (n= 239) and new post resection impairments were identified in 37.3% (n=117). Univariate analysis confirmed that new postoperative cognitive impairment [HR 7.91, 95% CI 2.47-25.33] and hemiplegia [HR 3.38, 95% CI 0.83-13.67] (not hemiparesis) impact OS. Risk stratified grouping by RPA demonstrated that gross total resection of contrast enhancing tumor in patients with no new postoperative neurological impairments confers the longest OS (median OS 27.1 months 95%CI 21.5-33.7). Patients with any residual tumor volume after surgery but no new neurological deficits experience a similar survival to younger patients (under 65) with 1 or more new postoperative neurological deficits (median OS 16.6 months 95%CI 15.2-19.2). Shortest OS is identified in patients with any volume of residual tumor plus 1 or more new postoperative neurological deficits and age over 65 (median OS 11.4 months, 95%CI 9.3-13.5). CONCLUSIONS This study confirms that new postoperative neurological impairments impact overall survival in patients with chemoradiation treated IDH-wild-type glioblastoma.
NCOG-69. SEX DIFFERENCES IN GLIOBLASTOMA PATIENT SURVIVAL AS A FUNCTION OF EXTENT OF SURGICAL RESECTION AND CYCLES OF ADJUVANT TEMOZOLOMIDE DURING STANDARD-OF-CARE REGIMENS
Lorence, Julia, White, Haylye, Rickertsen, Cassandra , Singleton, Kyle , Johnston, Sandra K. , Porter, Alyx B. , Mrugała, Maciej M. , Hu, Leland , Swanson, Kristin R. , Swanson, Kristin R , Bencomo, Tomas , Massey, Susan Christine , Hawkins‐Daarud, Andrea , Bendok, Bernard R. , Rubin, Joshua B

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii144-ii145

10.1093/neuonc/noaa215.607 Get It

Abstract OBJECTIVE Glioblastoma (GBM) is the most common malignant primary brain tumor in adults, with males more commonly affected than females(1.6:1). Despite advancements in treatments, prognosis is dismal with a median overall survival of 15 months. Our aim was to investigate sex as a variable in GBM patient survival after receiving incremental levels of standard-of-care treatment regimens – different extents of surgical resection and different numbers of cycles of adjuvant temozolomide chemotherapy. METHODS Drawing from our extensive multi-institutional brain tumor repository, we investigated GBM subjects with overall survival (OS), extent of resection (EOR), number of temozolomide (TMZ) cycles, and sex data (n=620, males: n=387, females: n=233). Cox proportional hazard ratios were computed to investigate the multivariable predictive value of the patient variables with OS. Patients were then divided into groups based on their sex, EOR (either biopsy, subtotal resection (STR) or gross total resection (GTR)), and TMZ cycles (I: < 6 cycles, II: 7-11 cycles and III: >12 cycles). RESULTS We observed that STR was beneficial for females (HR=0.52; CI=0.33-0.83; p-value=0.013), while for males the benefit was not detected (HR=0.73; CI=0.46-1.15; p-value=0.173) for STR but was detectable for GTR (HR=0.58, CI=0.37-0.90; p-value=0.014). Females receiving 7-11 cycles of TMZ showed a survival benefit (HR=0.52; CI=0.12-0.53; p-value=0.048) while males in the same group did not (HR=0.74; CI=0.46-1.19; p-value=0.21), in comparison to those in group I of TMZ cycles. No sex differences were identified in patients receiving < =6 cycles or >=12 cycles. CONCLUSION Together, our results contribute to the growing literature that sex differences exist in GBM patients, even in response to standard-of-care therapies. This should be accounted for when designing clinical trials for GBM so that we may advance our pursuit to deliver personalized medicine.
EPCO-07. LEVERAGING TRANSCRIPTOME SEQUENCING AND MATHEMATICAL MODELING TO INVESTIGATE GLIOBLASTOMA-MACROPHAGE INTERACTIONS
Urcuyo, Javier , Bruce, Jeffrey N. , Canoll, Peter , Hu, Leland , Swanson, Kristin R. , Swanson, Kristin R , Hawkins‐Daarud, Andrea , Massey, Susan Christine , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii70-ii70

10.1093/neuonc/noaa215.286 Get It

Abstract Glioblastoma (GBM) is the one of the most aggressive and common primary brain malignancies, with a poor median overall survival of less than 15 months. While the immune system is activated and brain-resident microglia and blood-derived macrophages combat the tumor, the tumor can convert some microglia and macrophages to instead exhibit an immune-suppressive phenotype. These co-opted immune cells are thereby termed ‘glioma-associated microglia and macrophages’ (GAMMs), as they allow for continued tumor growth. However, limited clinical data has been collected to understand this phenomenon. As a result, we have collected spatially-distributed image-localized biopsies from a cohort of patients and performed RNA sequencing on each sample. Correlations between normalized RNA counts of genetic markers for macrophages (i.e., CD68, CD163), tumor populations (i.e., SOX2, OLIG2), and key cell functions (i.e., KI67, CASP3) were analyzed. To further investigate the temporal effects that GAMMs have on GBM growth, we proposed the Proliferation-Invasion-Macrophage (PIM) model. This system of partial differential equations incorporates the proliferative and invasive behavior of GBM, as well as populations for both ‘healthy’ and ‘glioma-associated’ macrophages. By exploring the parameter space, we classified the various dynamics of tumor progression and how they relate to the immune response. With further insights of the interactions between GBM and macrophage populations, we can begin to parameterize the model on a patient-specific basis and provide insights to personalized immunotherapies and other novel immune-targeted treatments.
COVD-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT
Mrugała, Maciej M. , Pressley, Shelley M., Thomas, Alissa A. , Acquaye, Alvina , Haynes, Chas, Butowski, Nicholas , Hervey‐Jumper, Shawn L. , Porter, Alyx B. , Oliver, Kathy , Dunbar, Erin, Taylor, Jennie , Schiff, David , Nassiri, Farshad , Chang, Susan M. , Zadeh, Gelareh , Chheda, Milan G. , Ostrom, Quinn T. , Wefel, Jeffrey S. , Coven, Scott L. , Agnihotri, Sameer , Lim, Michael , Peters, Katherine B. , Hegi, Monika E. , Armstrong, Terri S. , Bent, Martin J. van den , Chang, Susan Marina

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii27-ii27

10.1093/neuonc/noaa215.112 Get It

Abstract To assess the impact of the pandemic on the field, we performed an international web-based survey of practitioners, scientists, and trainees from 21 neuro-oncology organizations across 6 continents from April 24 through May 17. Of 582 respondents, 258 (45%) were in the US, and 314 (55%) were international. 80.4% were affiliated with academic institutions. 94% respondents reported changes in clinical practice; 95% reported conversion to telemedicine for at least some appointments. However, almost 10% practitioners felt the need to see patients in person specifically because of billing concerns and perceived institutional pressure. Over 50% believed neuro-oncology patients were at increased risk of contracting COVID-19. 67% practitioners suspended enrollment for at least one clinical trial: 53% suspended phase II and 62% suspended phase III trial enrollment. 71% clinicians feared for their or their families’ safety, specifically because of their clinical duties. 20% percent said they did not have enough PPE to work safely; about the same percentage were unhappy with their institutions’ response to the pandemic. 43% believed the pandemic would negatively affect their academic career, and 52% fellowship program directors were worried about losing funding for their training programs. While 69% respondents reported increased stress, 44% were offered no psychosocial support. 37% had their salary reduced. 36% researchers had to temporarily close their laboratories. In contrast, the pandemic created positive changes in perceived patient and family satisfaction, quality of communication, and use of technology to deliver care and interactions with other practitioners. CONCLUSIONS: The pandemic has altered standard treatment schedules and limited investigational treatment options for patients. In some cases, clinicians felt institutional pressure to continue conducting billable in-person visits when telemedicine visits would have sufficed. A lack of institutional support created anxiety among clinicians and researchers. We make specific recommendations to guide clinical and scientific infrastructure moving forward.
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy
Biran, Anat, Purroy, Noelia, Lemvigh, Camilla K. , Clement, Kendell , Gruber, Michaela , Rassenti, Laura Z., Mohammad, Arman W., Lesnick, Connie , Shanafelt, Tait D. , Fernandes, Stacey M. , Brown, Jennifer R. , Wang, Lili , Li, Shuqiang , Livak, Kenneth J. , Klages, Sven , Timmermann, Bernd, Gnirke, Andreas , Wu, Catherine J. , Meissner, Alexander , Clement, Kendell , Gruber, Michaela , Kay, Neil E , Neuberg, Donna S , Campo, Elías , Wu, Catherine J , Shanafelt, Tait D , Kretzmer, Helene , Gu, Hongcang , Slager, Susan L. , Braggio, Esteban , Kay, Neil E. , Neuberg, Donna , Kipps, Thomas J. , Campo, Elı́as

Mayo Clinic

Blood Cancer Discovery | December 3, 2020 | Volume: 2 | Issue: 1 | Pages: 54-69

10.1158/2643-3230.bcd-19-0058 | PMID 33604581 Get It

Abstract Most human cancers converge to a deregulated methylome with reduced global levels and elevated methylation at select CpG islands. To investigate the emergence and dynamics of the cancer methylome, we characterized genome-wide DNA methylation in preneoplastic monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL), including serial samples collected across disease course. We detected the aberrant tumor-associated methylation landscape at CLL diagnosis and found no significant differentially methylated regions in the high-count MBL-to-CLL transition. Patient methylomes showed remarkable stability with natural disease and posttherapy progression. Single CLL cells were consistently aberrantly methylated, indicating a homogeneous transition to the altered epigenetic state and a distinct expression profile together with MBL cells compared with normal B cells. Our longitudinal analysis reveals the cancer methylome to emerge early, which may provide a platform for subsequent genetically driven growth dynamics, and, together with its persistent presence, suggests a central role in disease onset. Significance: DNA methylation data from a large cohort of patients with MBL and CLL show that epigenetic transformation emerges early and persists throughout disease stages with limited subsequent changes. Our results indicate an early role for this aberrant landscape in the normal-to-preneoplastic transition that may reflect a pan-cancer mechanism. See related commentary by Rossi, p. 6. This article is highlighted in the In This Issue feature, p. 1
A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer
Palomares, Melanie R. , Hageman, Lindsey , Chen, Yanjun , Landier, Wendy , Smith, Kandice, Umphrey, Heidi , Reich, Caroline A., Zamora, Kathryn , Armenian, Saro H. , Bevers, Therese B. , Henderson, Tara O. , Korde, Larissa A. , Melin, Susan A., Merajver, Sofía D. , Overholser, Linda , Pruthi, Sandhya , Wong, F. Lennie , Landier, Wendy , Smith, Kandice , Zamora, Kathryn W , Armenian, Saro H , Hudson, Melissa M , Garber, J. E. , Bhatia, Smita , Blaes, Anne , Hodgson, David , Hudson, Melissa M. , Garber, Judy E.

Mayo Clinic

Clinical Cancer Research | December 3, 2020 | Volume: 27 | Issue: 4 | Pages: 967-974

10.1158/1078-0432.ccr-20-3609 | PMID 33272980 Get It

Abstract Purpose: Low-dose tamoxifen reduces breast cancer risk, but remains untested in chest-irradiated cancer survivors—a population with breast cancer risk comparable with BRCA mutation carriers. We hypothesized that low-dose tamoxifen would be safe and efficacious in reducing radiation-related breast cancer risk. Patients and Methods: We conducted an investigator-initiated, randomized, phase IIb, double-blinded, placebo-controlled trial (FDA IND107367) between 2010 and 2016 at 15 U.S. sites. Eligibility included ≥12 Gy of chest radiation by age 40 years and age at enrollment ≥25 years. Patients were randomized 1:1 to low-dose tamoxifen (5 mg/day) or identical placebo tablets for 2 years. The primary endpoint was mammographic dense area at baseline, 1 and 2 years. IGF-1 plays a role in breast carcinogenesis; circulating IGF-1 and IGF-BP3 levels at baseline, 1 and 2 years served as secondary endpoints. Results: Seventy-two participants (low-dose tamoxifen: n = 34, placebo: n = 38) enrolled at a median age of 43.8 years (35–49) were evaluable. They had received chest radiation at a median dose of 30.3 Gy. Compared with the placebo arm, the low-dose tamoxifen arm participants had significantly lower mammographic dense area (P = 0.02) and IGF1 levels (P < 0.0001), and higher IGFBP-3 levels (P = 0.02). There was no difference in toxicity biomarkers (serum bone-specific alkaline phosphatase, lipids, and antithrombin III; urine N-telopeptide cross-links) between the treatment arms. We did not identify any grade 3–4 adverse events related to low-dose tamoxifen. Conclusions: In this randomized trial in chest-irradiated cancer survivors, we find that low-dose tamoxifen is effective in reducing established biomarkers of breast cancer risk and could serve as a risk-reduction strategy.
Is Levodopa Response a Valid Indicator of Parkinson's Disease?
Zhong, Qiaonan , Hartlein, Johanna M, Racette, Brad A. , Norris, Scott A. , Ushe, Mwiza, Maiti, Baijayanta , Criswell, Susan R. , Davis, Albert A. , Kotzbauer, Paul T. , Cairns, Nigel J., Perrin, Richard J. , Norris, Scott A , Davis, Albert A , Martin, W. R. Wayne , Miles, Michael, Perlmutter, Joel S.

Mayo Clinic

Movement Disorders | November 30, 2020 | Volume: 36 | Issue: 4 | Pages: 948-954

10.1002/mds.28406 | PMID 33253432 Get It

Abstract Background The clinical diagnosis of Parkinson's disease (PD) requires the presence of parkinsonism and supportive criteria that include a clear and dramatic beneficial response to dopaminergic therapy. Our aim was to test the diagnostic criterion of dopaminergic response by evaluating its association with pathologically confirmed diagnoses in a large population of parkinsonian patients. Methods We reviewed clinical data maintained in an electronic medical record from all patients with autopsy data who had been seen in the Movement Disorders Center at Washington University, St. Louis, between 1996 and 2018. All patients with parkinsonism who underwent postmortem neuropathologic examination were included in this analysis. Results There were 257 unique parkinsonian patients with autopsy‐based diagnoses who had received dopaminergic therapy. Marked or moderate response to dopaminergic therapy occurred in 91.2% (166/182) of those with autopsy‐confirmed PD, 52.0% (13/25) of those with autopsy‐confirmed multiple systems atrophy, 44.4% (8/18) of those with autopsy‐confirmed progressive supranuclear palsy, and 1 (1/8) with autopsy‐confirmed corticobasal degeneration. Other diagnoses were responsible for the remaining 24 individuals, 9 of whom had a moderate response to dopaminergic therapy. Conclusion A substantial response to dopaminergic therapy is frequent but not universal in PD. An absent response does not exclude PD. In other neurodegenerative disorders associated with parkinsonism, a prominent response may also be evident, but this occurs less frequently than in PD. © 2020 International Parkinson and Movement Disorder Society
Mary Ella Mascia Pierpont: Geneticist, scientist, mentor, friend (1945–2020)
Pierpont, Elizabeth I. , Berry, Susan A. , Lin, Angela E. , Lohr, Jamie L. , Schimmenti, Lisa A. , Dobyns, William B. , Schimmenti, Lisa A

Mayo Clinic

American Journal of Medical Genetics Part A | November 26, 2020 | Volume: 185 | Issue: 2 | Pages: 319-323

10.1002/ajmg.a.61963 | PMID 33241662 Get It

Exploratory Factor Analysis of the Vestibular Activities Avoidance Instrument
Dunlap, Pamela M. , Marchetti, Gregory F., Furman, Joseph M. , Delitto, Anthony , Whitney, Susan L. , Sparto, Patrick J. , Staab, Jeffrey P.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | November 25, 2020 | Volume: 147 | Issue: 2 | Pages: 144

10.1001/jamaoto.2020.4203 | PMID 33237289 Get It